SecProbe.io

Probe score transparency
Intelligence Terminal Search Topics Monthly Activity About

Probe Score Transparency

Quince Therapeutics, Inc. (QNCX)
Score window: May. 30, 2025 to May. 29, 2026

Back View Correspondence
Probe Score
2.5 / 10
Letters
1
Latest Activity
Feb. 12, 2026
Version
v1

Score Breakdown

Letter Count
1.0
Sentiment / Tone
0.5
Keywords
0.0
Signals
0.0
Notable 8-K Modifier
1.0
Notable 8-K Count
1

Matched Signals

No stored keyword or signal matches were recorded for this score.

Filings In This Window

DateFormSentimentUrgencySummaryOpen
Aug. 1, 2025 CORRESP Neutral/Informational Moderate Quince Therapeutics, Inc. has submitted a request to the SEC to expedite the effectiveness of their Registration Statement on Form S-3, which is scheduled for August 5, 2025. The … Read Filing EDGAR
Aug. 1, 2025 UPLOAD Neutral/Informational Low The SEC correspondence dated August 1, 2025, informs Dr. Dirk Thye, CEO of Quince Therapeutics, Inc., that the SEC has not reviewed and will not review the company's registration … Read Filing EDGAR

Notable 8-Ks In This Window

No notable 8-Ks were stored for this company in the score window.